Drug Profile
Insulin degludec biosimilar - GEROPHARM
Alternative Names: GP-40131; Insulin degludec - GEROPHARMLatest Information Update: 28 Jan 2023
Price :
$50
*
At a glance
- Originator GEROPHARM
- Class Antihyperglycaemics; Insulins; Pancreatic hormones
- Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Type 2 diabetes mellitus
Most Recent Events
- 28 Jan 2023 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Russia
- 04 Jan 2021 Preclinical development is ongoing in Russia (GEROPHARM pipeline, January 2021)
- 28 Oct 2020 No recent reports of development identified for preclinical development in Type-2-diabetes-mellitus in Russia